The early response of the postmenopausal endometrium to tamoxifen: Expression of estrogen receptors, progesterone receptors, and Ki-67 antigen

Menopause

Volumn 10, Issue 2, 2003, Pages 154-159

  Tregón, Maria Luisa ^a   Blümel, Juan Enrique ^b   Tarín, Juan J ^c   Cano, Antonio ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL BARROS LUCO TRUDEAU   (Chile)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Early response; Endometrium; Estrogen receptors; Ki 67; Progesterone receptors; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; POSTMENOPAUSE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; SCORING SYSTEM; UTERUS CAVITY; UTERUS PROLAPSE; VAGINAL HYSTERECTOMY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 0037866741     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200310020-00007     Document Type: Article

References (23)

1. Early Breast Cancer Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351:1451-1467.
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371-1388.
3. Cano A, Hermenegildo C. The endometrial effects of SERMs. Hum Reprod Update 2000;6:244-254.
4. Kommosss F, Karck U, Prompeler H., Pfisterer J, Kirkpatrick CJ. Steroid receptor expression in endometria from women treated with tamoxifen. Gynecol Oncol 1998;70:188-191.
5. Elkas J, Armstrong A, Pohl J, Cuttitta F, Martínez A, Gray K. Modulation of endometrial steroid receptors and growth regulatory genes by tamoxifen. Obstet Gynecol 2000;95:697-703.
6. Karck U, Kommoss F. Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast? Eur J Cancer 2000;36(Suppl 4):45-46.
7. Hashisuga T, Hideshima T, Kawarabayashi T, Eguchi F, Emoto M, Shirakusa T. Expression of steroid receptors, Ki-67, and epidermal growth factor receptor in tamoxifen-treated endometrium. Int J Gynecol Pathol 1999;18:297-303.
8. Carthew P, Edwards RE, Nolan BM, Tucker MJ, Smith LL. Compartmentalized uterotrophic effects of tamoxifen, toremifene, and estradiol in the ovariectomized Wistar (Han) rat. Toxicol Sci 1999; 48:197-205.
9. Karlsson S, Iatropoulos M J, Williams GM, Kangas L, Nieminen L. The proliferation in uterine compartments of intact rats of two different strains exposed to high doses of tamoxifen or toremifene. Toxicol Pathol 1998;26:759-768.
10. Christodoulacos G, Panoulis C, Botsis D, Rizos D, Kassanos D, Creatsas G. Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women. Maturitas 2002;42:77-84.
11. Kurman RJ, Norris HJ. Endometrial hyperplasia and related cellular changes. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract, 4th ed. New York: Springer-Verlag, 1994:411-437.
12. Sun J, Huang YR, Harrington WR, Shen S, Katzenellenbogen JA, Katzenellenbogen BS. Antagonists selective for estrogen receptor alpha. Endocrinology 2002;143:941-947.
13. Lessey BA, Killam AP, Metzger DA, Haney AF, Greene GL, McCarty KS. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab 1988;67:334-340.
14. Cano A, Hermenegildo C. Modulation of the oestrogen receptor: a process with distinct susceptible steps. Hum Reprod Update 2000; 6:207-211.
15. Tzukerman MT, Esty A, Santiso-Mere D, et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994;8:21-30.
16. McDonnell DP, Clemm DL, Hennan T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995;9:659-669.
17. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 1997;66:233-237.
18. Mourits M J, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review, Obstet Gynecol 2001;97:855-866.
19. Levy C, Robel P, Gautray JP, et al. Estradiol and progesterone receptors in human endometrium: normal and abnormal menstrual cycles and early pregnancy. Am J Obstet Gynecol 1980;136:646-651.
20. Cameron ST, Critchley HO, Thong KJ, Buckley CH, Williams AR, Baird DT. Effects of daily low dose mifepristone on endometrial maturation and proliferation, Hum Reprod 1996;11:2518-2526.
21. Felix JC, Farahmand S. Endometrial glandular proliferation and estrogen receptor content during the normal menstrual cycle. Contraception 1997;55:19-22.
22. Schwartz LB, Krey L, Demopoulos R, Goldstein SR, Nachtigall LE, Mittal K. Alterations in steroid hormone receptors in the tamoxifentreated endometrium. Am J Obstet Gynecol 1997;176:129-137.
23. Cohen I, Altaras MM, Beyth Y, et al. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifcn and progestogens. Gynecol Oncol 1997;65:83-88.